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Abstract 
Background: Currently, there is no information on whether in-hospital heart rate (HR) 
reduction has an influence on risk of death or rehospitalization. The study evaluates the 
relation between in-hospital HR reduction in heart failure (HF) patients on mortality and 
rehospitalization within one-year observation. 
Methods: The analysis included hospitalized Polish patients with sinus rhythm from the 
European Society of Cardiology Heart Failure Pilot (ESC-HF-Pilot) and ESC Heart Failure 
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Long-Term Registries (ESC-HF-LT), who were divided into two groups: reduced HR and 
not-reduced HR. HR reduction was defined as a reduced value of HR at discharge compared 
to admission HR. The primary endpoint (PE) was one-year all-cause death, the secondary 
endpoint (SE) was one-year all-cause death or rehospitalization for worsening HF. 
Results: The final analysis included 747 patients; 491 reduced HR (65.7%) and 256 not-
reduced HR (34.3%). The PE occurred in 58/476 (12.2%) from reduced HR group and in 
26/246 (10.5%) from not-reduced HR group (p = 0.54). In the reduced HR group, independent 
predictors of PE were age, New York Heart Association (NYHA) class at admission, serum 
sodium level at admission and systolic blood pressure at discharge. In the not-reduced HR 
group the independent predictor of PE was diastolic blood pressure at discharge. The SE was 
observed in 180 patients, 124/398 (31.2%) from reduced HR and 56/207 (27.1%) from the 
not-reduced HR group (p = 0.30). In the not-reduced HR group only angiotensin converting-
enzyme inhibitor usage at discharge was independently associated with lower risk of the SE.  
Conclusions: In-hospital HR reduction did not influence on the outcomes of HF patients in 
sinus rhythm.  
Key words: heart failure, registry, prognosis, heart rate, hospitalization 
 
 
Introduction 
Although the treatment of heart failure (HF) has been improving in recent decades, the 
outcome of HF patients is still not satisfactory [1, 2]. Increasing prevalence of HF in 
developing countries is a great challenge for contemporary cardiology. Proper identification 
of risk factors of death or rehospitalization is crucial for the management of HF patients.  
The most comprehensive and reliable data concerning the risk factors and outcome of 
patients with HF come from international observation registries. The European Society of 
Cardiology (ESC) created the Heart Failure Pilot (ESC-HF-Pilot) and Heart Failure Long-
Term (ESC-HF-LT) Registries to assess the clinical characteristics and outcome of HF 
patients in clinical practice in European countries. Recently published analyses of data from 
both Registries revealed several risk factors associated with one-year outcomes in hospitalized 
HF patients [1, 3–6]. One of the modifiable predictors of cardiovascular mortality and 
morbidity is heart rate (HR), which is associated with poor prognosis in general population, 
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patients with hypertension, coronary artery disease and HF [2, 7–11]. Laskey et al. [12] 
reported, that higher HR at discharge in hospitalized HF patients significantly increased the 
risk of death or rehospitalization. However, there is still no information on whether in-hospital 
reduction of HR modifies risk of death or rehospitalization. 
The aim of the current analysis was to evaluate the influence of in-hospital HR reduction 
in HF patients with sinus rhythm (SR) on mortality and/or rehospitalization over a one-year 
observation period.   
 
Methods 
Study population 
In the present analysis, data from two prospective, multicenter registries were included: 
ESC-HF-Pilot and ESC-HF-LT [1, 2, 13, 14]. The ESC-HF-Pilot Registry included data 
gathered between October 2009 and May 2010 in 136 European centers, including 29 centers 
localized in Poland. The ESC-HF-LT Registry consists of three phases, including data from 
211 centers in 21 European countries. The I phase of the ESC-HF-LT Registry was conducted 
between May 2011 and April 2013 and enrolled patients one day per week for the whole year. 
Adult patients (at least 18 years old) with newly-diagnosed HF (using clinical, biochemical 
and echocardiographic findings) or worsening of HF were enrolled in the Registries. The 
ESC-HF-Pilot and ESC-HF-LT Registries recruited patients hospitalized for HF and 
outpatients seen in ambulatory care. Exclusion criteria were not specified. All patients signed 
an informed consent. The study was approved by the local Ethical Review Board. 
In the current analysis only hospitalized Polish patients enrolled in the ESC-HF-Pilot and 
in phase I of the ESC-HF-LT Registry in SR were taken into account. Atrial fibrillation/atrial 
flutter and/or paced rhythm on 12-lead electrocardiogram (ECG), as well as lack of ECG 
recording during index hospitalization were excluded from the current analysis.  
All data according to the medical history, concomitant diseases and clinical status at 
admission and hospital discharge were obtained. Follow-up of the patients lasted one year. 
During the follow-up data regarding all-cause death and readmission for HF worsening were 
collected. 
 
Study groups 
 Patients were divided into two groups according to HR difference during index 
hospitalization from admission to discharge: with or without HR reduction. HR values were 
assessed during standard physical examination. HR reduction was defined as a reduced value 
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of HR recorded at discharge in comparison to the value observed upon admission. Patients 
with HR reduction (reduced-HR group) and without HR reduction (not-reduced-HR group) 
during index hospitalization were compared in regard to demographics, medical history, 
clinical status and pharmacotherapy at the moment of admission, during index hospitalization 
and at hospital discharge.   
 
Endpoints 
 In both Registries, the primary endpoint was one-year all-cause death, whereas the 
secondary endpoint was composed of one-year all-cause death or rehospitalization for 
worsening HF. 
 
Statistical analysis 
 Normality of distribution of variables was assessed using the Shapiro-Wilk test. 
Continuous non-normally distributed variables were presented as median values and 
interquartile range (IQR). Categorical data were presented as percentage and absolute 
frequencies. Statistical significance of differences between groups was assessed: for 
quantitative variables with U Mann-Whitney test and for qualitative variables — with Fisher 
exact test. Cox proportional hazard regression models were used to determine predictors of 
the primary and secondary endpoints. Only variables with p < 0.1 in univariate analysis were 
included in multivariate analysis. A value of p < 0.05 was considered significant for all tests. 
Statistical analysis performed using SAS® software, version 9.4.  
 
Study group selection 
Overall, in all European countries 5118 patients were enrolled in the ESC-HF-Pilot 
Registry and 12,440 patients in the ESC-HF-LT Registry. The Polish cohorts of the ESC-HF-
Pilot and ESC-HF-LT Registries included 630 and 743 HF patients who were discharged after 
index hospitalization, respectively. Firstly, 139 patients were excluded from the current 
analysis, because of paced rhythm observed in ECG recording. Secondly, 460 patients with 
present atrial fibrillation/atrial flutter during index hospitalization were excluded from further 
analysis. Other rhythms or lack of ECG were noted in 27 patients. Finally, ECG recordings on 
admission and discharge were available for 747 (100%) patients. The flow chart of patient 
enrollment in the analysis is shown in Figure 1. HR reduction was observed in 491 of 747 
(65.7%) patients, while lack of HR reduction in 256/747 (34.3%) patients included in the 
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study. Follow-up data  was excluded for 25 patients, resulting from a lack of  response after 
direct, investigator contact.  
 
Results  
Study group characteristics 
 Median age in the group analyzed was 67.0 (57.6–77.0) years, 68.5% of patients were 
male. Median HR value at admission in the total population was 80 (70–90) beats per minute 
(bpm). In the reduced HR group median HR at admission was 84 (75–100) bpm, whereas in 
the not-reduced HR group 70 (60–75) bpm (p < 0.0001). Furthermore, median HR value at 
discharge was 70 (64–78) bpm in the population analyzed, 70 (62–75) bpm in the reduced HR 
group and 72 (68–80) bpm in the not-reduced HR group (p < 0.0001). Median value of HR 
reduction in the reduced HR group was 15 bpm (IQR: 8–25 bpm). The reduced HR group 
more frequently had hypertension (71.0% vs. 63.3%; p = 0.04) and less frequently used 
antiplatelets before the index hospitalization (58.2% vs. 69.4%; p = 0.003) in comparison to 
the not-reduced HR group. According to clinical status at admission, the reduced HR group 
had higher New York Heart Association (NYHA) class (3 [2–4] vs. 3 [2–3]; p = 0.02), higher 
systolic blood pressure (SBP) (131 [120–150] vs. 130 [110–140]; p = 0.002), higher diastolic 
blood pressure (DBP) (80 [70–90] vs. 80 [70–84]; p = 0.0005) and more frequently were 
admitted because of acute coronary syndrome ([ACS] 27.5% vs. 20.7%; p = 0.04). Moreover, 
reduced HR group had a longer duration of index hospitalization (7 [4–11] vs. 6 [3–9]; p = 
0.004), in comparison to the not-reduced HR group. A full comparison of both groups in 
regard to baseline characteristics, clinical course of index hospitalization, in-hospital and 
long-term outcomes are presented in Table 1. As shown in Table 2, HR at admission was 
significantly higher in the ESC-HF-Pilot population in comparison to the group enrolled in 
the ESC-HF-LT Registry (80 [70–95] vs. 78 [68–90]; p = 0.02). The comparison between 
these two Registries did not show  significant differences in regard to HR at discharge, mean 
HR reduction during hospitalization or the percentage of patients who achieved HR reduction 
(Table 2). 
One-year outcomes 
Moreover, no significant differences were observed between groups in occurrence of 
primary and secondary endpoints. In comparison of reduced HR and not-reduced HR groups, 
hazard ratios of prevalence of primary and secondary endpoints were 1.16 (95% confidence 
Interval [CI] 0.73–1.84; p = 0.54) and 1.15 (95% CI 0.85–1.56; p = 0.38), respectively. 
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Kaplan-Meier curves present outcomes of reduced HR and not-reduced HR groups are shown 
in Figure 2.    
Primary endpoint 
 In the population analyzed, 722 patients completed one-year follow-up and primary 
endpoint occurred in 84/722 patients (11.6%). In the reduced HR group, primary endpoint 
was observed more frequently (58/476, 12.2%), than in the not-reduced HR group (26/246, 
10.5%; p = 0.54). Tables 3 and 5 present risk factors for one-year all-cause death in univariate 
analysis in the reduced HR and not-reduced HR groups, respectively. In the multivariate 
analysis only older age, higher NYHA class at admission, lower serum sodium at admission 
and lower SBP at discharge were revealed to be independent predictors of primary endpoint in 
the reduced HR group (Table 4). In multivariate analysis only lower DBP at discharge 
remained to be a statistically significant predictor of one-year all-cause death in the not-
reduced HR group, as shown in Table 6.  
 
Secondary endpoint 
 In the total population, data on one-year follow-up were available for 605 patients. In 
the whole analyzed group, secondary endpoint was observed in 180 (29.8%) patients, 124/398 
(31.2%) from the reduced HR and 56/207 (27.1%) from the not-reduced HR group (p = 0.30). 
Tables 3 and 5 present risk factors for secondary endpoint in univariate analysis in the 
reduced HR and not-reduced HR groups, respectively. In the reduced HR group, the 
multivariate analysis did reveal these factors to reach statistical significance (Table 4). 
However, there were trends for diabetes, history of stroke, higher NYHA class at admission 
and lower serum sodium at admission towards independent prediction of secondary endpoint 
in the reduced HR group. In the not-reduced HR only the use of ACEI at discharge was 
independently associated with lower risk of all-cause death or rehospitalization for worsening 
HF, as presented in Table 6. 
 
Discussion 
The current study has revealed that HR reduction during the hospitalization for HF 
was not associated with benefits in patients with SR. Moreover, predictors of all-cause death 
or combined endpoint (death or rehospitalization for worsening HF) at one year were partly 
comparable in patents with and without HR reduction during index hospitalization.  
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 Among numerous demographic and clinical factors, only a few of them differed 
between patients with and without in-hospital HR reduction. In the reduced-HR group  higher 
NYHA class was observed. Not much is known about the correlation between NYHA class 
and HR at hospital admission. However, Ahmed et al. [15] revealed no significant differences 
in HR at admission and NYHA class I–II vs. III–IV in patients with HF with preserved 
function of the left ventricle. Moreover, results from the current analysis showed that in the 
reduced HR group, higher NYHA class at admission is significantly related to all-cause death 
at one year. These findings are consistent with results of previous analyses performed in 
hospitalized HF patients enrolled in the ESC-HF-Pilot and ESC-HF-LT Registries [1, 3, 4].  
In the present analysis, the reduced HR group less frequently used beta-blockers (BBs) 
prior to admission in comparison to the not-reduced HR group, however this observation did 
not reach the statistical significance. Moreover, without significance, the analysis of in-
hospital pharmacotherapy showed a higher percentage of patients receiving BBs in the 
reduced HR group. At discharge, the reduced HR group more often had been prescribed BBS. 
A lower percentage of patients receiving BBs during index hospitalization and at discharge 
may, at least partially, result from a higher occurrence of chronic obstructive pulmonary 
disease in this group. 
 Additionally, in the HR reduction group a higher percentage of patients presented with 
ACS as a cause of admission. Sokol Myftiu et al. [16] reported that,  in patients presenting 
with acute myocardial infarction (AMI) the group with HF upon admission had significantly 
higher HR at admission in comparison to the AMI without HF group. Moreover, myocardial 
infarction may be a reason for BB implementation, which contributes to a reduction of HR. 
Several recent clinical trials and population-based studies reported significant 
associations between HR and outcomes in patients with HF. Previous analysis of the ESC-HF 
Pilot Registry showed that higher HR at admission was associated with worse clinical course 
during index hospitalization [5]. The placebo-subgroup analysis of patients with stable 
coronary artery disease and left-ventricular dysfunction enrolled in the BEAUTIFUL 
(morBidity — mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary 
disease and left ventricULar dysfunction) study revealed, that a baseline resting HR  70 bpm 
in comparison to HR < 70 bpm is associated with a significantly higher risk of several 
outcomes, including cardiovascular death, admission to hospital for HF, admission to hospital 
for myocardial infarction and coronary revascularization [9]. Moreover, in the SHIFT 
(Systolic Heart failure treatment with the If inhibitor ivabradine Trial) trial conducted on 
patients with chronic HF, the placebo-treated group with HR values ≥ 87 bpm had 
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significantly higher risk for the primary composite endpoint (cardiovascular death or hospital 
admission for worsening HF) in comparison to the placebo-treated patients with HR 70 to 72 
bpm [17]. In the ivabradine-treated group patients with HR < 60 bpm at 28 days of treatment 
the primary composite endpoint occurred less frequently during the observation in comparison 
to the group of patients with higher values of HR and the observed effect of ivabradine was 
shown to be HR reduction-dependent [17]. The ESC-HF-Pilot and ESC-HF-LT Registries did 
not include information concerning the in-hospital use of ivabradine.. The analysis of 
hospitalized HF with reduced ejection fraction (HFrEF) patients enrolled in the EVEREST 
(Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial 
showed, that baseline HR was not associated with all-cause mortality. However at the level of 
≥ 70 bpm, each 5-beat increase observed at 1 and 4 weeks following discharge was a predictor 
of all-cause mortality [18]. The study conducted by Kapoor et al. [19] enrolled patients with 
HF with preserved ejection fraction (HFpEF) revealed that all-cause mortality at one year is 
significantly higher in patients with HR ≥ 60 bpm or more in comparison to the group with 
HR < 60 bpm. An interestingly high prevalence of digoxin usage was observed in both 
subgroups in the present analysis, however no difference between subgroups was observed. It 
is worth noting, that patients with paroxysmal atrial fibrillation were not excluded from the 
analysis and overall frequency of digoxin usage during the first years of data gathering was 
higher. 
Analysis performed by Bui et al. [20] of HF hospitalized patients enrolled in the Get 
With The Guidelines-Hart Failure program showed a J-shaped correlation of in-hospital 
mortality and HR, whereas the lowest mortality rate was observed within HR values between 
70 bpm and 75 bpm, moreover, higher HR at admission is independently associated with 
higher in-hospital mortality [20]. The analysis of the Acute Decompensated Heart Failure 
Syndromes [21] Registry revealed, that in patients hospitalized for acute HF lower baseline 
HR is associated with a significantly higher rate of in-hospital cardiac death [22]. Moreover, 
Lancellotti et al. [23] reported, that increased HR at 24–36 h following admission for acute 
HF is related to a higher risk of in-hospital mortality. The impact of higher HR at discharge 
on poor prognosis of HF patients has also been reported [24]. Habal et al. [24] analyzed a 
group of discharged HF patients and revealed a significant increase in all-cause one-month 
mortality for the value of discharge HR  81 bpm in comparison to the control group with HR 
61–70 bpm. Moreover, the group of patients with HR > 90 bpm had significantly increased 
risk of one-year all-cause mortality when compared to the controls (HR 40–60 bpm) and also 
had higher rate of HF readmissions and cardiovascular disease within 30 days [24].  
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Laskey et al. [12] reported, in patients with SR HR  75 bpm at hospital discharge 
increased the risk of one-month and one-year mortality and composite outcome of mortality 
and all-cause rehospitalization. The data concerning the impact of HR reduction on the 
prognosis of HF patients remains controversial. The results of the BEAUTIFUL study 
revealed no significant difference in the primary composite endpoint (cardiovascular death, 
admission to hospital for AMI and admission to hospital for new-onset or worsening HF) 
between ivabradine- and placebo-treated group [25]. However, in the subgroup of patients 
with HR  70 bpm, treatment with ivabradine significantly reduced the occurrence of 
coronary endpoints — admission to hospital for myocardial infarction (fatal and non-fatal), 
admission to hospital for myocardial infarction or unstable angina and coronary 
revascularization. In the present study only one patient from the HR reduction group was 
using ivabradine and this difference between the two analyzed groups of patients did not 
reach statistical significance. The Cardiac Insufficiency BIsoprolol Study II (CIBIS II) study 
revealed, that the lowest baseline HR and greatest HR changed during 2 months following 
inclusion due to bisoprolol usage in HF patients significantly reducing one-year mortality and 
HF admission rate [10]. Li et al. [26] reported, that in- and outpatients with HFrEF in SR, who 
were enrolled in the Swedish Heart Failure Registry, had significant relation of higher HR 
with increased mortality. BB use significantly reduced HR in comparison to non-treated group 
and was related to reduced mortality, however, treatment with BBs did not change the 
association between HR and all-cause mortality [26]. In the present analysis, differences in 
usage of BB were observed. Compared with the not-reduced HR group, in the HR reduced 
group fewer patients used BBs before admission and more of them used BBs at discharge 
from the hospital. However, these discrepancies did not reach statistical significance.  
 
Conclusions 
The current study evaluates the impact of in-hospital HR reduction during 
hospitalization in HF patients on one-year mortality and rehospitalization. The results of the 
present study revealed that HR reduction during hospitalization for HF is not associated with 
outcome of patients with SR. Moreover, predictors of PE and SE were similar in patients with 
and without HR reduction during index hospitalization.  
 
Conflict of interest: None declared 
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Table 1. Baseline characteristics, clinical course of index hospitalization, in-hospital and long-term outcomes of 
the reduced HR and not-reduced HR groups. 
 Total (n = 747) Not-reduced HR (n = 
256)  
Reduced HR (n = 491)  
Demographics 
Age [years] 
67.0 (57.6–77.0); n = 
747 
67.0 (58.0–76.7); n = 256 67.0 (57.6–77.0); n = 491 0.92 
Male 68.5%; 512/747 70.7%; 181/256 67.4%; 331/491 0.41 
BMI [kg/m2] 
27.7 (24.7–31.2); n = 
708 
27.7 (24.9–30.6); n = 244 27.7 (24.5–31.6); n = 464 0.76 
Heart failure 
LVEF [%] 35 (25–50); n = 669 37 (26–50); n = 213 35 (25–50); n = 456 0.70 
Medical history 
Hypertension 68.4%; 510/746 63.3%; 162/256 71.0%; 248/490 0.04 
Coronary artery disease 61.5%; 459/746 64.5%; 165/256 60.0%; 294/490 0.33 
Peripheral artery disease 12.5%; 92/747 11.3%; 29/256 12.8%; 63/491 0.64 
Diabetes 33.7%; 252/747 33.2%; 85/256 34.0%; 167/491 0.87 
Chronic kidney disease 18.2%; 136/746 17.2%; 44/256 18.8%; 92/490 0.62 
COPD 16.4%; 122/745 12.6%; 32/255 18.4%; 90/490 0.05 
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Stroke 7.8%; 58/746 5.5%; 14/256 9.0%; 44/490 0.11 
Previous pharmacotherapy 
Diuretics 62.2%; 452/727 66.3%; 167/252 60.0%; 285/475 0.11 
Aldosterone antagonist 40.0%; 291/727 43.7%; 110/252 38.1%; 181/475 0.15 
ACE-I 62.6%; 455/727 65.1%; 164/252 61.3%; 291/475 0.33 
ARB 9.8%; 71/725 8.4%; 21/251 10.6%; 50/474 0.43 
Beta-blocker 72.6%; 527/726 75.4%; 190/252 71.1%; 337/474 0.22 
Statins 57.2%; 415/726 61.5%; 165/252 54.9%; 260/474 0.10 
Ivabradine 0.3%; 1/391 0.0%; 0/145 0.4% 1/246 1.00 
Antiplatelets 62.1%; 451/726 69.4%; 175/252 58.2%; 276/474 0.003 
Clinical status at admission 
Cardiogenic shock 1.8%; 13/708 1.3%; 3/237 2.1%; 10/471 0.56 
NYHA class 3 (2–4); n = 743 3 (2–3); n = 256 3 (2–4); n = 487 0.02 
NYHA I 1.4% 10/719 1.6% 4/256 1.3% 6/487  
NYHA II 28.7% 206/719 31.3% 80/256 27.5% 129/487  
NYHA III 44.1% 317/719 48.1% 123/256 43.1% 201/487  
NYHA IV 35.9% 186/719 19.1% 49/256 28.1% 137/487  
SBP [mmHg] 
130 (114–150); n = 
745 
130 (110–140); n = 255 131 (120–150); n = 490 0.002 
DBP [mmHg] 80 (70–90); n = 745 80 (70–84); n = 255 80 (70–90); n = 490 0.0005 
Heart rate [bpm] 80 (70–90); n = 747 70 (60–75); n = 256 84 (75–100); n = 491 < 0.0001 
QRS duration [ms] 
102 (91–120); n = 
673 
102 (92–121); n = 227 102 (90–120); n = 446 0.67 
ACS as a cause of 
admission 
25.2%; 188/746 20.7%; 53/256 27.5%; 135/490 0.04 
Laboratory findings at admission 
Serum sodium [mmol/L] 
139.0 (136.0–141.0); 
n = 738 
139.0 (136.0–141.0); n = 
252 
139.0 (136.6–141.0); n = 
486 
0.39 
Serum potassium 
[mmol/L] 
4.4 (4.1–4.8); n = 738 4.49 (4.12–4.83); n = 252 4.40 (4.06–4.76); n = 486 0.06 
Serum creatinine 
[mg/dL] 
1.05 (0.87–1.32); n = 
725 
1.01 (0.85–1.30); n = 248 1.07 (0.89–1.33); n = 477 0.11 
Hemoglobin [g/dL] 
13.4 (12.3–14.6); n = 
734 
13.4 (12.1–14.7); n = 251 13.4 (12.4–14.6); 
 n =  483 
0.61 
Major management and pharmacotherapy during index hospitalization, clinical status at discharge 
PCI/CABG during 
hospitalization 
16.8%; 125/745 16.1%; 41/254 17.1%; 84/491 0.76 
Beta-blocker 89.9% (670/745) 87.4% (222/254) 91.2% (448/491) 0.12 
Digoxin 15.0% (112/745) 14.1% (36/254) 15.5% (76/491) 0.67 
Amiodarone 10.6% (79/745) 8.7% (22/254)  11.6% (57/491) 0.26 
Antiarrhythmics 4.0% (30/745) 5.1% (13/254) 3.5% (17/491) 0.33 
Heart rate [bpm] 70 (64–78); n = 747 72 (68–80); n = 256 70 (62–75); n = 491 < 0.0001 
SBP [mmHg] 
120 (110–130); n = 
744 
120 (110–130); n = 255 120 (110–130); n = 489 0.91 
DBP [mmHg] 70 (65–80); n = 742 70 (65–80); n = 254 70 (65–80); n = 488 0.16 
Pharmacotherapy at hospital discharge 
Diuretics 82.1%; 613/747 79.3%; 203/256 83.5%; 410/491 0.16 
Aldosterone antagonist 
63.1%; 471/746 65.2%; 167/256 62.0%; 304/490 0.42 
ACEI 77.5%; 579/747 77.3%; 198/256 77.6%; 381/491 0.93 
ARB 10.6%; 79/745 9.2%; 23/255 11.4%; 56/490 0.38 
Beta-blocker 89.3%; 667/747 87.1%; 223/256 90.4%; 444/491 0.17 
Statins 74.7%; 558/747 73.4%; 188/256 75.4%; 370/491 0.60 
Antiplatelets 78.9%; 589/747 78.9%; 202/256 78.8%; 387/491 1.00 
Ivabradine 0.5%; 2/391 0.0%; 0/145 0.8; 2/246 0.53 
In-hospital outcome 
Hospitalization length 7 (4–10); n = 722 6 (3–9); n = 246 7 (4–11); n = 476 0.004 
 13 
[days] 
One-year outcome 
One-year all-cause death 11.6%; 84/722 10.5%; 26/246 12.2%; 58/476 0.54 
One-year all-cause death 
or rehospitalization due 
to the HF worsening 
29.8%; 180/605 27.1%; 56/207 31.2%; 124/398 0.30 
Bolded values indicate p-values < 0.05. ACEI — angiotensin converting enzyme inhibitor; ACS — acute 
coronary syndrome; ARB — angiotensin receptor blocker; BMI — body mass index; CABG — coronary artery 
bypass grafting; COPD — chronic obstructive pulmonary disease; DBP — diastolic blood pressure; LVEF — 
left ventricular ejection fraction; NYHA — New York Heart Association; PCI — percutaneous coronary 
intervention; SBP — systolic blood pressure 
 
 
 
Table 2. Comparison of patients enrolled in the ESC-HF-Pilot and ESC-HF-LT Registries in regard to heart rate 
(HR) values. 
 ESC-HF-Pilot 
Registry 
ESC-HF-LT 
Registry 
P 
HR at admission [bpm] 80 (70–95) 78 (68–90) 0.02 
HR at discharge [bpm] 70 (65–78) 70 (62–77) 0.16 
Median HR reduction during hospitalization [bpm] 10 (0–20) 6 (0–20) 0.06 
Patients who achieved HR reduction 68.9% 62.9% 0.09 
Bolded values indicates p-values < 0.05. ESC-HF-Pilot — European Society of Cardiology Heart Failure Pilot; 
ESC-HF-LT — European Society of Cardiology Long-Term 
 
 
 
Table 3. Univariate analysis of predictors of primary and secondary endpoints at one year in the reduced heart 
rate (HR) group. 
 Primary endpoint Secondary endpoint 
 Hazard ratio (95% CI) P Hazard ratio (95% CI) P 
Demographics 
Age, per 10 years 1.71 (1.34–2.17) < 0.0001 1.12 (0.97–1.28) 0.12 
     
Male 0.77 (0.45–1.29) 0.32 0.81 (0.57–1.16) 0.26 
BMI, per 1 kg/m2 0.93 (0.88–0.98) 0.01 0.99 (0.96–1.02) 0.63 
Heart failure 
LVEF, per 5% 0.98 (0.89–1.08) 0.67 0.83 (0.74–0.94) 0.004 
Medical history 
Hypertension 1.04 (0.58–1.85) 0.90 0.77 (0.53–1.12) 0.17 
Coronary artery disease 0.99 (0.58–1.67) 0.96 1.30 (0.91–1.86) 0.15 
Peripheral artery disease 1.76 (0.92–3.40) 0.09 1.27 (0.77–2.09) 0.35 
Diabetes 1.41 (0.83–2.37) 0.20 1.43 (1.01–2.03) 0.04 
Chronic kidney disease 2.02 (1.16–3.52) 0.01 1.78 (1.22–2.60) 0.003 
COPD 1.29 (0.70–2.39) 0.42 1.33 (0.89–2.00) 0.17 
Stroke 0.94 (0.37–2.34) 0.89 1.91 (1.16–3.14) 0.01 
Clinical status at admission  
NYHA class, per 1 class  2.09 (1.44–3.04) 0.0001 1.66 (1.32–2.10) < 0.0001 
SBP, per 10 mmHg 0.95 (0.87–1.04) 0.28 0.89 (0.84–0.95) 0.0004 
DBP, per 10 mmHg 0.97 (0.82–1.14) 0.68 0.90 (0.81–1.01) 0.07 
Heart rate, per 10 bpm 1.10 (0.98–1.23) 0.11 1.05 (0.97–1.13) 0.25 
QRS reduction, per 10 ms 1.06 (0.96–1.18) 0.25 1.05 (0.98–1.12) 0.20 
Cardiogenic shock 1.53 (0.37–6.27) 0.56 1.36 (0.50–3.67) 0.55 
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VF or VT as a cause of 
admission 
0.96 (0.35–2.65) 0.94 0.90 (0.46–1.76) 0.75 
ACS as a cause of 
admission 
1.30 (0.75–2.26) 0.32 1.06 (0.72–1.58) 0.77 
Laboratory findings at admission  
Serum sodium, per 1 
mmol/L  
0.89 (0.85–0.94) < 0.0001 0.94 (0.90–0.97) 0.001 
Serum potassium, per 1 
mmol/L 
0.90 (0.57–1.42) 0.64 0.83 (0.61–1.14) 0.25 
Serum creatinine, per 1 
mg/dL 
1.27 (0.94–1.72) 0.13 1.28 (1.03–1.59) 0.02 
Hemoglobin, per 1 g/dL 0.83 (0.72–0.94) 0.004 0.88 (0.81–0.97) 0.01 
Major management during index hospitalization, clinical status and laboratory findings at discharge 
PCI/CABG during 
hospitalization 
0.84 (0.41–1.82) 0.70 1.04 (0.63–1.71) 0.88 
Heart rate, per 10 bpm 1.31 (1.02–1.68) 0.03 1.15 (0.97–1.37) 0.10 
SBP, per 10 mmHg 0.72 (0.60–0.85) 0.0001 0.78 (0.70–0.88) < 0.0001 
DBP, per 10 mmHg 0.70 (0.54–0.91) 0.008 0.74 (0.62–0.88) 0.0006 
Pharmacotherapy at hospital discharge 
Diuretics 1.31 (0.62–2.75) 0.48 1.44 (0.88–2.72) 0.15 
Aldosterone antagonist 0.84 (0.50–1.42) 0.52 1.24 (0.87–1.77) 0.24 
ACEI 0.60 (0.34–1.03) 0.06 0.69 (0.48–1.01) 0.05 
ARB 0.73 (0.29–1.82) 0.50 1.12 (0.66–1.89) 0.70 
Beta-blocker 0.47 (0.24–0.91) 0.02 0.82 (0.49–1.38) 0.45 
Pharmacotherapy prior hospital admission 
Diuretics 1.27 (0.73–2.21) 0.40 1.66 (1.13–2.42) 0.009 
Aldosteron antagonist 0.84 (0.48–1.45) 0.52 1.13 (0.79–1.60) 0.51 
ACEI 1.35 (0.77–2.37) 0.29 1.03 (0.72–1.47) 0.89 
ARB 1.00 (0.43–2.34) 0.99 1.07 (0.62–1.83) 0.81 
Βeta-blocker 0.91 (0.52–1.61) 0.75 1.07 (0.72–1.60) 0.72 
Statins 0.65 (0.38–1.10) 0.11 1.09 (0.77–1.56) 0.62 
Antiplatelets 1.19 (0.69–2.07) 0.54 1.22 (0.85–1.76) 0.28 
Bolded values indicate p-values < 0.05. ACEI — angiotensin converting enzyme inhibitor; ACS — acute 
coronary syndrome; ARB — angiotensin receptor blocker; BMI — body mass index; CABG — coronary artery 
bypass grafting; CI — confidence interval; COPD — chronic obstructive pulmonary disease; DBP — diastolic 
blood pressure; LVEF — left ventricular ejection fraction; NYHA — New York Heart Association; PCI — 
percutaneous coronary intervention; SBP — systolic blood pressure; VF — ventricular fibrillation; VT — 
ventricular tachycardia 
 
 
Table 4. Multivariate analysis of predictors of primary and secondary endpoints at one year in the reduced HR 
group. 
Primary endpoint  Secondary endpoint  
 Hazard ratio 
(95% CI) 
P  Hazard ratio 
(95% CI) 
P 
Age, per 10 years 1.58 (1.22–2.07) < 0.001 LVEF, per 5% 0.96 (0.90–1.02) 0.209 
BMI, per 1 kg/m2 0.96 (0.91–1.02) 0.217 Diabetes 1.40 (0.96–2.05) 0.080 
Chronic kidney 
disease 
1.44 (0.74–2.81) 0.280 Chronic kidney 
disease 
1.34 (0.85–2.10) 0.206 
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NYHA class at 
admission 
1.66 (1.09–2.54) 0.019 
Stroke 
1.62 (0.92–2.85) 0.096 
Serum sodium at 
admission, per 1 
mmol/dl 
0.91 (0.86–0.97) 0.003 
NYHA class at 
admission 
1.29 (0.98–1.68) 0.065 
Hemoglobin at 
admission, per 1 
g/dL 
0.98 (0.82–1.16) 0.790 
SBP at admission, 
per 10 mmHg 
0.89 (0.76–1.04) 0.297 
Heart rate at 
discharge, per 10 
bpm 
0.98 (0.72–1.33) 0.886 Serum sodium at 
admission, per 1 
mmol/dL 
0.96 (0.92–1.00) 0.058 
SBP at discharge, 
per 10 mmHg 
0.67 (0.51–0.87) 0.003 Serum creatinine 
at admission, per 1 
mg/dl 
1.07 (0.77–1.49) 0.688 
DBP at discharge, 
per 10 mmHg 
1.27 (0.85–1.89) 0.242 Hemoglobin at 
admission, per 1 
g/dL 
0.99 (0.85–1.03) 0.188 
Beta-blocker at 
discharge 
0.84 (0.35–2.01) 0.697 SBP at discharge, 
per 10 mmHg 
0.89 (0.76–1.04) 0.140 
Statins at 
discharge 
0.52 (0.26–1.02) 0.057 DBP at discharge, 
per 10 mmHg 
1.03 (0.81–1.31) 0.827 
 
  Prior diuretics 
usage 
1.23 (0.82–1.87) 0.320 
Bolded values indicates p-values < 0.05. BMI — body mass index; DBP — diastolic blood pressure; LVEF — 
left ventricular ejection fraction; NYHA — New York Heart Association; SBP — systolic blood pressure 
 
 
 
Table 5. Univariate analysis of predictors of primary and secondary endpoints at one year in the not-reduced 
heart rate (HR) group. 
 Primary endpoint Secondary endpoint 
 Hazard ratio (95% CI) P Hazard ratio (95% CI) P 
Demographics 
Age, per 10 years 1.46 (1.05–2.02) 0.02 1.13 (0.92–1.38) 0.24 
Male 0.81 (0.36–1.82) 0.61 0.88 (0.51–1.51) 0.63 
BMI, per 1 kg/m2 0.95 (0.87–1.04) 0.24 0.97 (0.92–1.02) 0.24 
Heart failure 
LVEF, per 5% 0.78 (0.56–1.07) 0.12 0.80 (0.65–0.98) 0.03 
Medical history 
Hypertension 1.66 (0.70–3.96) 0.25 0.84 (0.50–1.41) 0.50 
Coronary artery disease 2.35 (0.89–6.23) 0.09 2.45 (1.27–4.72) 0.01 
Peripheral artery disease 1.57 (0.54–4.56) 0.41 1.33 (0.63–2.80) 0.45 
Diabetes 1.81 (0.84–3.92) 0.14 1.06 (0.61–1.82) 0.84 
Chronic kidney disease 1.97 (0.83–4.69) 0.13 1.85 (1.03–3.32) 0.04 
COPD 2.10 (0.84–5.23) 0.11 1.47 (0.74–2.89) 0.27 
Stroke 0.00 (0.00–) 0.99 0.97 (0.30–3.10) 0.96 
Clinical status at admission  
NYHA class, per 1 class  1.93 (1.13–3.31) 0.02 1.38 (0.97–1.94) 0.07 
SBP, per 10 mmHg 0.98 (0.84–1.13) 0.75 0.95 (0.85–1.06) 0.36 
DBP, per 10 mmHg 0.69 (0.52–0.91) 0.009 0.87 (0.72–1.06) 0.17 
Heart rate, per 10 bpm 0.96 (0.68–1.37) 0.83 1.30 (1.03–1.64) 0.03 
QRS duration, per 10 ms 1.08 (0.96–1.22) 0.18 1.04 (0.94–1.14) 0.42 
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Cardiogenic shock 0.00 (0.00–) 0.99 0.00 (0.00–) 0.99 
VF or VT as a cause of 
admission 
0.30 (0.04–2.18) 0.23 0.61 (0.25–1.53) 0.30 
ACS as a cause of 
admission 
0.63 (0.22–1.83) 0.40 0.88 (0.46–1.69) 0.70 
Laboratory findings at admission  
Serum sodium, per 1 
mmol/L  
0.90 (0.82–0.99) 0.03 0.90 (0.84–0.97) 0.003 
Serum potassium, per 1 
mmol/L 
1.52 (0.85–2.72) 0.15 1.19 (0.77–1.83) 0.43 
Serum creatinine, per 1 
mg/dL 
1.89 (1.27–2.80) 0.002 1.42 (1.03–1.97) 0.04 
Hemoglobin, per 1 g/dL 0.84 (0.72–0.99) 0.04 0.89 (0.79–0.996) 0.04 
Major management during index hospitalization, clinical status and laboratory findings at discharge 
PCI/CABG during 
hospitalization 
0.44 (0.10–0.87) 0.27 0.67 (0.30–1.48) 0.32 
Heart rate, per 10 bpm 1.05 (0.87–1.28) 0.59 1.06 (0.95–1.19) 0.31 
SBP, per 10 mmHg 0.79 (0.62–1.00) 0.053 0.80 (0.68–0.93) 0.005 
DBP, per 10 mmHg 0.56 (0.42–0.82) 0.0015 0.97 (0.57–0.94) 0.016 
Pharmacotherapy at hospital admission 
Diuretics 2.31 (0.87–6.12) 0.09 2.61 (1.36–5.03) 0.004 
Aldosterone antagonist 1.16 (0.53–2.55) 0.71 1.82 (1.08–3.06) 0.02 
ACEI 0.97 (0.43–2.21) 0.95 0.96 (0.56–1.65) 0.89 
ARB 0.46 (0.06–3.39) 0.44 0.95 (0.38–2.38) 0.92 
Βeta-blocker 1.36 (0.51–3.62) 0.54 1.28 (0.68–2.41) 0.45 
Pharmacotherapy prior hospital discharge 
Diuretics 0.93 (0.37–2.32) 0.88 1.22 (0.63–2.35) 0.55 
Aldosterone antagonist 1.21 (0.32–2.78) 0.65 1.59 (0.89–2.86) 0.12 
ACEI 0.38 (0.18–0.84) 0.02 0.42 (0.25–0.72) 0.001 
ARB 0.40 (0.06–2.97) 0.37 0.82 (0.33–2.04) 0.67 
Βeta-blocker 0.68 (0.26–1.81) 0.44 0.71 (0.37–1.38) 0.31 
Statins 0.87 (0.38–1.99) 0.74 1.04 (0.58–1.84) 0.90 
Antiplatelets 0.75 (0.31–1.78) 0.51 1.04 (0.56–1.92) 0.91 
Bolded values indicate p-values < 0.05. ACEI — angiotensin converting enzyme inhibitor; ACS — acute 
coronary syndrome; ARB — angiotensin receptor blocker; BMI — body mass index; CABG — coronary artery 
bypass grafting; COPD — chronic obstructive pulmonary disease; DBP — diastolic blood pressure; LVEF — 
left ventricular ejection fraction; NYHA — New York Heart Association; PCI — percutaneous coronary 
intervention; SBP — systolic blood pressure; VF — ventricular fibrillation; VT — ventricular tachycardia 
 
 
 
Table 6. Multivariate analysis of predictors of primary and secondary endpoints at one year in the not–reduced 
heart rate (HR) group. 
Primary endpoint  Secondary endpoint  
 Hazard ratio 
(95% CI) 
P  Hazard ratio 
(95% CI) 
P 
Age, per 10 years 1.25 (0.88–1.78) 0.213 LVEF, per 5% 0.95 (0.83–1.08) 0.422 
NYHA class at 
admission 
1.73 (0.93–3.21) 0.082 Coronary artery 
disease 
2.13 (0.92–4.93) 0.078 
DBP at admission, per 
10 mmHg 
0.90 (0.69–1.18) 0.432 Chronic kidney 
disease 
1.38 (0.68–2.83) 0.377 
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Serum sodium at 
admission, per 1 
mmol/dL 
0.96 (0.85–1.07) 0.434 Serum sodium at 
admission, per 1 
mmol/dL 
0.95 (0.86–1.04) 0.259 
Serum creatinine at 
admission, per 1 
mg/dL 
1.62 (0.98–2.70) 0.061 Serum creatinine at 
admission, per 1 
mg/dL 
1.02 (0.59–1.77) 0.942 
Hemoglobin at 
admission, per 1 g/dL 
0.93 (0.74–1.17) 0.543 Hemoglobin at 
admission, per 1 
g/dL 
0.97 (0.82–1.14) 0.684 
DBP at discharge, per 
10 mmHg 
0.64 (0.43–0.95) 0.026 SBP at discharge, 
per 10 mmHg 
0.90 (0.68–1.19) 0.441 
ACEI at discharge 
0.79 (0.30–2.04) 0.619 DBP at discharge, 
per 10 mmHg 
1.09 (0.70–1.69) 0.705 
 
  Prior aldosterone 
antagonist usage 
1.22 (0.60–2.49) 0.584 
 
  Prior diuretics 
usage 
1.99 (0.84–4.72) 0.118 
   ACEI at discharge 0.48 (0.23–0.99) 0.047 
Bolded text indicates p-values < 0.05. ACEI — angiotensin converting enzyme inhibitor; BMI — body mass 
index; DBP — diastolic blood pressure; LVEF — left ventricular ejection fraction; NYHA — New York Heart 
Association; SBP — systolic blood pressure 
 
 
FIGURE LEGEND: 
 
Figure 1. The flow chart of patient recruitment in the study. 
 
Figure 2. Kaplan-Meier curves in the reduced HR and not-reduced HR groups; A. For all-
cause 12-month mortality; B. For all-cause 12-month mortality or hospitalization.  
 
 


